OABI vs OGI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
OABI presents a contradictory profile: while the Piotroski F-Score of 6/9 indicates stable financial health and the balance sheet is strong with low debt and high liquidity, the operational data is alarming. Revenue is declining sharply (-22.5% YoY), and the stock is in a severe technical downtrend with bearish insider activity from the CEO and CFO. Despite a 'Strong Buy' analyst consensus and a high price target, the fundamental divergence between shrinking top-line growth and high Price/Sales valuation suggests significant risk.
OGI exhibits severe financial fragility, highlighted by a weak Piotroski F-Score of 2/9 and a negative operating margin of -5.38%. While the stock appears undervalued relative to its Graham Number ($2.21) and Price-to-Book ratio (0.77), the intrinsic value is significantly lower at $0.77. Strong top-line revenue growth of 48.7% is currently offset by a poor earnings track record and a concerning spike in Forward P/E (from 13.82 to 84.44), suggesting a projected collapse in earnings. The company is essentially a speculative play on revenue growth that has yet to prove operational sustainability.
Compare Another Pair
Related Comparisons
OABI vs OGI: Head-to-Head Comparison
This page compares OmniAb, Inc. (OABI) and Organigram Global Inc. (OGI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.